Centessa Pharmaceuticals Files 2025 Proxy Statement
Ticker: CNTA · Form: DEF 14A · Filed: May 6, 2025 · CIK: 1847903
| Field | Detail |
|---|---|
| Company | Centessa Pharmaceuticals PLC (CNTA) |
| Form Type | DEF 14A |
| Filed Date | May 6, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, shareholder-meeting
TL;DR
Centessa proxy filed. Vote on directors & auditors.
AI Summary
Centessa Pharmaceuticals plc filed its definitive proxy statement on May 6, 2025, for its annual meeting of shareholders. The filing outlines the company's governance, executive compensation, and proposals to be voted on by shareholders, including the election of directors and the ratification of its independent registered public accounting firm.
Why It Matters
This filing provides shareholders with crucial information to make informed voting decisions on company leadership and corporate governance matters.
Risk Assessment
Risk Level: low — This is a routine annual filing providing information to shareholders and does not indicate any immediate operational or financial risks.
Key Players & Entities
- Centessa Pharmaceuticals plc (company) — Registrant
- May 6, 2025 (date) — Filing Date
- 20250620 (date) — Conformed Period of Report
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Definitive Proxy Statement, is filed by a company to solicit shareholder votes on important matters such as the election of directors, executive compensation, and other corporate actions.
When was Centessa Pharmaceuticals plc's definitive proxy statement filed?
Centessa Pharmaceuticals plc filed its definitive proxy statement on May 6, 2025.
What is the 'Conformed Period of Report' for this filing?
The conformed period of report for this filing is 20250620.
What is the Standard Industrial Classification (SIC) code for Centessa Pharmaceuticals plc?
The Standard Industrial Classification code for Centessa Pharmaceuticals plc is 2834, which corresponds to Pharmaceutical Preparations.
What are the key items shareholders will vote on according to this proxy statement?
While the provided text doesn't detail the specific proposals, a definitive proxy statement typically includes votes on the election of directors, ratification of the independent registered public accounting firm, and potentially advisory votes on executive compensation.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on May 6, 2025 regarding Centessa Pharmaceuticals plc (CNTA).